ATE509012T1 - Arylindenopyrimidine und ihre verwendung als adenosin-a2a-rezeptorantagonisten - Google Patents

Arylindenopyrimidine und ihre verwendung als adenosin-a2a-rezeptorantagonisten

Info

Publication number
ATE509012T1
ATE509012T1 AT08841729T AT08841729T ATE509012T1 AT E509012 T1 ATE509012 T1 AT E509012T1 AT 08841729 T AT08841729 T AT 08841729T AT 08841729 T AT08841729 T AT 08841729T AT E509012 T1 ATE509012 T1 AT E509012T1
Authority
AT
Austria
Prior art keywords
arylindenopyrimidines
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT08841729T
Other languages
English (en)
Inventor
Brian C Shook
Paul F Jackson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE509012T1 publication Critical patent/ATE509012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08841729T 2007-10-25 2008-10-23 Arylindenopyrimidine und ihre verwendung als adenosin-a2a-rezeptorantagonisten ATE509012T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98245607P 2007-10-25 2007-10-25
PCT/US2008/080923 WO2009055548A1 (en) 2007-10-25 2008-10-23 Arylindenopyrimidines and their use as adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
ATE509012T1 true ATE509012T1 (de) 2011-05-15

Family

ID=40225283

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08841729T ATE509012T1 (de) 2007-10-25 2008-10-23 Arylindenopyrimidine und ihre verwendung als adenosin-a2a-rezeptorantagonisten

Country Status (13)

Country Link
US (1) US20090111804A1 (de)
EP (1) EP2220053B1 (de)
JP (1) JP2011500833A (de)
CN (1) CN101835760A (de)
AR (1) AR069026A1 (de)
AT (1) ATE509012T1 (de)
AU (1) AU2008316821A1 (de)
CL (1) CL2008003184A1 (de)
PA (1) PA8801401A1 (de)
PE (1) PE20091345A1 (de)
TW (1) TW200934496A (de)
UY (1) UY31421A1 (de)
WO (1) WO2009055548A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
AU2003275430A1 (en) * 2003-10-03 2005-05-19 Ortho-Mcneil Pharmaceutical, Inc. Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist

Also Published As

Publication number Publication date
TW200934496A (en) 2009-08-16
US20090111804A1 (en) 2009-04-30
UY31421A1 (es) 2009-04-30
AR069026A1 (es) 2009-12-23
WO2009055548A1 (en) 2009-04-30
CL2008003184A1 (es) 2009-10-16
PA8801401A1 (es) 2009-05-15
JP2011500833A (ja) 2011-01-06
AU2008316821A1 (en) 2009-04-30
CN101835760A (zh) 2010-09-15
EP2220053A1 (de) 2010-08-25
EP2220053B1 (de) 2011-05-11
PE20091345A1 (es) 2009-09-24

Similar Documents

Publication Publication Date Title
BRPI0716936A2 (pt) derivados de adenosina como antigonistas de receptor de a2a
ATE481409T1 (de) Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
DE602007012308D1 (de) Bicyclische pyrimidinone und deren verwendung
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
PL2552909T3 (pl) Pochodne 4-aminopirymidyny i ich zastosowanie jako antagonistów receptorów adenozynowych a2a
DE602005016162D1 (de) Benzimidazolderivate und ihre Verwendung als AII Rezeptor-Antagonist
DE602007013869D1 (de) Substituierte imidazole und ihre verwendung als pestizide
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE502040T1 (de) Bisadenosinverbindungen als adenosin-a2a- rezeptoragonisten
ATE548355T1 (de) 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
ATE538130T1 (de) Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
ATE486856T1 (de) Benzimidazol-derivate und ihre verwendung zur modulierung des gabaa-rezeptor-komplexes
ATE493400T1 (de) Pyridin- und pyrimidinderivate als mglur2- antagonisten
SI2188291T1 (sl) Zliti biciklični pirimidini
ATE550355T1 (de) Antikörper gegen ccr5 und ihre verwendung
ATE544752T1 (de) Aryloxyacetamidderivate und ihre verwendung als fungizide
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties